Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Short Interest Update

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) saw a significant growth in short interest during the month of June. As of June 30th, there was short interest totaling 3,592 shares, a growth of 92.7% from the June 15th total of 1,864 shares. Based on an average daily volume of 7,451 shares, the short-interest ratio is presently 0.5 days. Currently, 0.1% of the company’s stock are sold short.

Invesco Biotechnology & Genome ETF Price Performance

Shares of PBE stock traded up $1.56 during mid-day trading on Thursday, hitting $91.08. 1,263 shares of the stock traded hands, compared to its average volume of 6,909. Invesco Biotechnology & Genome ETF has a 52-week low of $63.92 and a 52-week high of $94.06. The stock has a market cap of $285.99 million, a P/E ratio of 20.44 and a beta of 0.70. The stock’s fifty day moving average is $85.48 and its two-hundred day moving average is $82.43.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada boosted its stake in Invesco Biotechnology & Genome ETF by 22.3% in the 1st quarter. Royal Bank of Canada now owns 75,402 shares of the company’s stock worth $4,783,000 after purchasing an additional 13,767 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Invesco Biotechnology & Genome ETF by 5.9% in the first quarter. Goldman Sachs Group Inc. now owns 37,657 shares of the company’s stock worth $2,389,000 after buying an additional 2,103 shares during the last quarter. Osaic Holdings Inc. lifted its stake in shares of Invesco Biotechnology & Genome ETF by 9.9% during the second quarter. Osaic Holdings Inc. now owns 9,441 shares of the company’s stock worth $605,000 after buying an additional 852 shares during the period. PNC Financial Services Group Inc. grew its holdings in shares of Invesco Biotechnology & Genome ETF by 74.5% during the third quarter. PNC Financial Services Group Inc. now owns 574 shares of the company’s stock valued at $40,000 after buying an additional 245 shares during the last quarter. Finally, Blair William & Co. IL grew its holdings in shares of Invesco Biotechnology & Genome ETF by 150.0% during the third quarter. Blair William & Co. IL now owns 1,000 shares of the company’s stock valued at $70,000 after buying an additional 600 shares during the last quarter.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.